Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CFB | P00751 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091761 | 0.87 | CFB (0.38) | P2RX7CFBRENHTR2ANOS2 | |
| SCHEMBL15629848 | 0.87 | REN (0.36) | P2RX7CFBRENKDM4EALDH1A1 | |
| SCHEMBL15590132 | 0.74 | CFB (0.39) | P2RX7CFB | |
| SCHEMBL15629885 | 0.73 | CFB (0.40) | P2RX7CFBRENALDH1A1NOS2 | |
| SCHEMBL16783918 | 0.73 | POLB (0.35) | P2RX7CFBRENKDM4EALDH1A1 | |
| SCHEMBL18975746 | 0.71 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL3801326 | 0.71 | SKP2 (0.37) | KDM4EALDH1A1HPGDHSD17B10NOS2 | |
| SCHEMBL28836116 | 0.70 | CFB (0.43) | CFBKDM4EHPGDSKP2 | |
| SCHEMBL16091748 | 0.68 | NOS2 (0.37) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL16091752 | 0.67 | MAPT (0.39) | KDM4EALDH1A1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | P2RX7 2309/4885CFB 3808/4885REN 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.